Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Patrys Ltd

PAB.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.02

▼ -3.13%

Market Cap $14.76M · Vol 108.40K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$14.76M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

25.00

Momentum

Beta

2.45

vs Market

52W High

$0.04

40.30% below

52W Low

$0.01

127.98% above

Volume

108.40K

Avg 238.07K

P/B

3.23

Price-to-book

ROE

N/A

Return on equity

Free Float

69.83%

Public shares

Shariah Compliance8 STANDARDS

✗ Patrys Ltd (PAB.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PAB.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-11.43%

-20.51%

+0.00%

-11.43%

YTD

+10.71%

+106.67%

-64.50%

-92.87%

Financials & Valuation

TTM · Annual

Total Revenue	$545.18K
Net Income	$-1,982,747.00
Revenue Growth (YoY)	-99.69%
Gross Margin	100.00%
Operating Margin	-327.03%
Net Profit Margin	-363.69%
ROE	N/A
ROA · ROIC	-102.13% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	2.49
P/B	3.23
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	674.85M

Technical Indicators

50-Day SMA	$0.03
200-Day SMA	$0.02
RSI (14)	25.00
Beta	2.45
52-Week High	$0.04
52-Week Low	$0.01

Volume Today	108.40K
Avg Daily Volume (30D)	238.07K
Relative Volume	0.46x
Volatility (10D)	50.42
Volatility (30D)	58.16
Free Float	69.83%

Analyst Consensus

N/A

Current Price $0.02

Mean Target $0.09

52W Low$0.01 52W High$0.04

Current

Target

$0.01 $0.04

Current Analyst target

+318.76% upside potential · 0 analysts

Identifiers

ExchangeASX

FIGIBBG001SNQ2X7

ISINAU000000PAB9

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.